Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Meningiomas

Meningiomas, which account for about 40% of primary central nervous system tumors, have significant psychological and social impacts, even without treatment. Their effect on quality of life is often underestimated and poorly documented. There is one validated questionnaire (MQOL) but it has not yet been translated into French. The project involves two phases: first, translating and linguistically validating the MQOL into French; second, scientifically validating the questionnaire with 50 meningioma patients using established scales (EQ-5D, Karnofsky, FACT-Br) to ensure its reliability and internal consistency.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Quality of Life Central Nervous System Neoplasms Meningeal Neoplasms Meningioma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Nerve Tissue Neoplasms, Vascular Tissue Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

GHU Paris -Psychiatrie & Neurosciences

Paris, 15014, France

Location status: Recruiting

Location contact

Johan PALLUD, Pr

CONTACT

[email protected]

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient aged 18 years or older
Diagnosis of intracranial meningioma confirmed by imaging or surgery

Exclusion criteria

Pregnant or breastfeeding women (Article L1121-5)
Patients deprived of liberty by judicial or administrative decision, as well as individuals undergoing psychiatric care (Article L1121-6)
Patients not fluent in French or with poor understanding of the language
Inability to refuse participation in the study

Treatment and study plan

Quality of life

Other

The four questionnaires (MQOL, EQ-5D, Karnofsky, and FACT-Br) will be sent to patients online using the secure online platform Redcap.

Primary outcomes

meningioma-specific quality-of-life questionnaire

Time frame: 1 month

The meningioma-specific quality-of-life questionnaire (MQOL) is an self-administered questionnaires and a validated tool used in practice in English, specifically applicable to patients with meningiomas, and was developed by a Canadian team (Baba A, Saha A, McCradden MD, Boparai K, Zhang S, Pirouzmand F, Edelstein K, Zadeh G, Cusimano MD. Development and validation of a patient-centered, meningioma-specific quality-of-life questionnaire. J Neurosurg. 2021 May 14;135(6):1685-1694. doi: 10.3171/2020.11.JNS201761. PMID: 33990085.)

This project will involve applying the MQOL to a population of 50 patients and comparing it with self-administered questionnaires already validated in French practice (FACT-Br, Karnofsky, and EQ-5D).

The purpose of all these questionnaires is to assess quality of life in patients.

The EQ-5D and Karnofsky evaluate it in a general manner, while the FACT-Br is used in an oncological context.

Study contacts

Contact information is provided by the study sponsor or research team.

Benoît HUDELIST, Dr

CONTACT

[email protected]

Viviane AWASSI

CONTACT

[email protected]

01.45.65.84.86

Sponsors and collaborators

Lead sponsor

Centre Hospitalier St Anne

Other

Registry information

Acronym: MenQOL

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Jun 29, 2025
Registry last updated: Jun 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting